Literature DB >> 32450176

Galectins as potential pharmacological targets in renal injuries of diverse etiology.

Ming Gu1, Xianglin Mei2, Yanan Zhao3.   

Abstract

Galectins are carbohydrate-binding proteins, and their importance in renal diseases of diverse etiology has been documented. Amongst different galectins, the role of galectin-3 in the pathophysiology of renal diseases has been well documented. There is an increase in galectin-3 in the circulation as well as on the kidneys in chronic kidney disease patients. The increase in galectin-3 is negatively correlated with a decrease in renal function and overall survival rate. The preclinical studies also correlate the increase in galectin-3 levels with renal dysfunction. Accordingly, scientists have exploited galectin-3 as a potential pharmacological target to improve renal functions in different preclinical models of renal injury. Apart from galectin-3, there have been few studies documenting the role of galectin-1, 8, and 9 in renal diseases. The role of galectin-1 is not clearly identified, and there have been conflicting reports regarding its role in renal diseases. Galectin-8 and 9 impart renoprotective effects as per clinical and preclinical studies, respectively. The present review discusses the role of different galectins in renal diseases of diverse etiology.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diabetes; Galectins; Glomerulus; Injury; Kidney; Nephropathy

Mesh:

Substances:

Year:  2020        PMID: 32450176     DOI: 10.1016/j.ejphar.2020.173213

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

Review 1.  Unraveling How Tumor-Derived Galectins Contribute to Anti-Cancer Immunity Failure.

Authors:  Diego José Laderach; Daniel Compagno
Journal:  Cancers (Basel)       Date:  2021-09-09       Impact factor: 6.575

2.  Novel Galectin-3 Inhibitors for Treating Fibrosis.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-01-11       Impact factor: 4.345

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.